Overview

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Status:
Completed

Trial end date:
2017-07-04

Target enrollment:

Participant gender:

Summary

The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors. The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Immunoconjugates
Maytansine